Bo Jan Noordman

Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study

Bo Jan Noordman, Manon C.W. Spaander, Roelf Valkema et al. · The Lancet Oncology · 2018 · 320 citations

Residual Disease, Surgical Oncology, Esophageal Cancer +11

Effectiveness of First‐Line Treatment With Recombinant Interleukin‐1 Receptor Antagonist in Steroid‐Naive Patients With New‐Onset Systemic Juvenile Idiopathic Arthritis: Results of a Prospective Cohort Study

Sebastiaan J. Vastert, Wilco de Jager, Bo Jan Noordman et al. · Arthritis & Rheumatology · 2013 · 257 citations

Effect of Neoadjuvant Chemoradiotherapy on Health-Related Quality of Life in Esophageal or Junctional Cancer: Results From the Randomized CROSS Trial

Bo Jan Noordman, Mathilde G. E. Verdam, Sjoerd M. Lagarde et al. · Journal of Clinical Oncology · 2017 · 121 citations · Full text

Impact of neoadjuvant chemoradiotherapy on health-related quality of life in long-term survivors of esophageal or junctional cancer: results from the randomized CROSS trial

Bo Jan Noordman, Mathilde G. E. Verdam, Sjoerd M. Lagarde et al. · Annals of Oncology · 2017 · 81 citations · Full text

Multimodality treatment for esophageal adenocarcinoma: multi-center propensity-score matched study

Sheraz R. Markar, Bo Jan Noordman, H Mackenzie et al. · Annals of Oncology · 2016 · 80 citations · Full text